VANDA PHARMACEUTICALS INC (VNDA)
Health Care · specialty pharmaceuticals · NASDAQ
Vanda Pharmaceuticals is a specialty biopharmaceutical company commercializing psychiatric and neurological therapies while advancing a pipeline focused on pharmacogenetic-driven precision medicine.
What VANDA PHARMACEUTICALS INC does
Vanda Pharmaceuticals is a global biopharmaceutical company focused on the development and commercialization of innovative therapies for high unmet medical needs in psychiatry and neurology. The company utilizes pharmacogenetics and pharmacogenomics to guide its drug discovery, clinical development, and commercial positioning. Its product portfolio includes treatments for schizophrenia, bipolar I disorder, Non-24-hour sleep-wake disorder, and multiple sclerosis, alongside a pipeline of investigational drugs for various conditions.
Recent developments
BYSANTI received FDA approval in Q1 2026 for bipolar I disorder and schizophrenia, with a launch expected in the second half of 2026. NEREUS launched commercially in the U.S. in Q2 2026, and the company expects clinical trial results for three Phase III programs before the end of 2026. The PDUFA target action date for Quimilza (imsidolimab) is December 12, 2026.
From VANDA PHARMACEUTICALS INC's filing of 2026-08-06.
Themes: psychiatry, neurology, sleep disorders, multiple sclerosis, precision medicine, pharmacogenetics, rare diseases, dermatology
Fundamentals
- Price$4.01 as of 2026-10-21 close
- Market cap$242M as of 2026-07-30 (share count; price 2026-10-21)
- 1-year return-24.2% 2025-10-21 close $5.29 → 2026-10-21 close $4.01
- P/En/a negative earnings
- Net margin-102.0% FY2025, SEC XBRL
- ROE-67.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+8.7% FY2025, SEC XBRL
- Revenue CAGR (3y)-5.3% SEC XBRL
- Beta0.64 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How VNDA compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $51M | -$64M | -$63M | -$1.04 | -$31M† | $190000† |
| Q1 FY2026 2026-03-31 | $52M | -$50M | -$49M | -$0.82 | -$50M | $221000 |
| Q4 FY2025 2025-12-31 | $57M† | -$40M† | -$141M† | -$2.39† | -$29M† | $102000† |
| Q3 FY2025 2025-09-30 | $56M | -$31M | -$23M | -$0.38 | -$32M† | $161000† |
| Q2 FY2025 2025-06-30 | $53M | -$39M | -$27M | -$0.46 | -$15M† | $299000† |
| Q1 FY2025 2025-03-31 | $50M | -$41M | -$29M | -$0.50 | -$33M | $436000 |
| Q4 FY2024 2024-12-31 | $53M† | -$10M† | -$5M† | -$0.09† | -$2M† | $214000† |
| Q3 FY2024 2024-09-30 | $48M | -$11M | -$5M | -$0.09 | -$15M† | $161000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$56M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How VANDA PHARMACEUTICALS INC looks technically
VANDA PHARMACEUTICALS INC (VNDA) is trading 37.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 79 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30). It just made a new 20-day low, breaking below its recent trading range. It is 1.1% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 37.1% below its 200-day average, the long-term trend line — a long-term downtrend | -37.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.98 | $4.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.38 | $6.38 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 5.33. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 79 trading days ago — a "death cross", a bearish long-term signal | 79 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control | 36.3 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30) | 26.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.96 to $4.85) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 5.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.94 | $9.94 |
|---|---|---|
| From the 52-week high | it is 59.7% below its 52-week high (its highest price of the past year) | -59.7% |
| Above the 52-week low | it is 1.1% above its 52-week low (its lowest price of the past year) | +1.1% |
| Below the 52-week high | it is 59.7% below its highest point of the past year | 59.7% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $33.44 (set on 2018-12-03) | $33.44 |
| Given back of the 52-week move | over the past year its closes ranged ($4.01 to $9.56), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.44 to $7.62. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 88.0% below its all-time high | -88.0% |
| Nearest price level | it is trading 4.5% above a support level at $3.83 — a price it turned at twice since 2025-04-09, most recently on 2025-05-15. Since 2024-10-21 it has 1 such level below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.5% |
| All-time low | its lowest closing price on record is $0.45 (set on 2008-12-23) | $0.45 |
| Above the all-time low | it is 791.1% above its all-time low | +791.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1951 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1951 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.85 and $5.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.85 – $4.55 – $5.25 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 12.1 daily ranges below its 200-day average price (37.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.05× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 4.3% gap down opened on 2026-10-15 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.2 percentage points (the stock lost 22.3% while the market lost 0.1%) | -22.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 30.1 percentage points (the stock lost 26.8% while the market gained 3.3%) | -30.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 50.7 percentage points (the stock lost 40.9% while the market gained 9.8%) | -50.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 39.4 percentage points (the stock lost 24.2% while the market gained 15.2%) | -39.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.8% of the share price. | -23.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 42% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.90 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -41.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is under water. That average is $4.96 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | -19.1% |
Price levels it has turned at before
VNDA last closed at $4.01 on 2026-10-21. Since 2024-10-21 it has turned at 1 price below its last close and 13 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.83 | Support | 4.5% below the last close | turned there twice · 2025-04-09 to 2025-05-15 |
| $4.21 | Resistance | 5.1% above the last close | turned there four times · 2025-02-03 to 2025-06-03 |
| $4.35 | Resistance | 8.4% above the last close | turned there three times · 2025-02-25 to 2025-09-16 |
| $4.45 | Resistance | 10.9% above the last close | turned there twice · 2024-12-11 to 2026-08-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $5.33.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 16 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Oversold (14-day RSI below 30) · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$11.75 range $5.75 – $20.00; median $11.00
Analyst estimates, as of 2026-10-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Significant historical and ongoing net losses; dependence on continued success of key products like Fanapt and HETLIOZ.","High dependence on successful development, regulatory approval, and commercialization of new pipeline assets.","Extensive competition and potential pricing pressures in core psychiatric and neurological treatment markets."]
What changed in the latest 10-Q
AI-assisted comparison of VNDA's 10-Q filed 2026-05-07 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- BYSANTI™ now listed as separately approved commercial product (2026-05-07 filing)
- NEREUS™ now listed as commercial product (2026-05-07 filing)
- BYSANTI™ received FDA approval for bipolar I disorder and schizophrenia (2026-05-07 filing)
- BYSANTI™ protected by data exclusivity through February 20, 2031 and patents expiring May 31, 2044 (2026-05-07 filing)
- NEREUS™ now commercially available nationwide through direct-to-consumer platform nereus.us (2026-05-07 filing)
- Fanapt® weekly TRx reached 11-year high of over 2,600 prescriptions for week ending April 24, 2026 (2026-05-07 filing)
- FDA accepted BLA for imsidolimab in GPP with PDUFA target action date of December 12, 2026 (2026-05-07 filing)
- Pivotal imsidolimab clinical study results published in April 28, 2026 issue of New England Journal of Medicine Evidence (2026-05-07 filing)
- Phase III study of VQW-765 for social anxiety disorder with results expected by end of 2026 (2026-05-07 filing)
- VQW-765 described as alpha-7 nicotinic acetylcholine receptor partial agonist (2026-05-07 filing)
- VGA-157A ASO molecule for Parkinson's disease added to pipeline (2026-05-07 filing)
- NEREUS™ listed for prevention of vomiting induced by motion (2026-05-07 filing)
- NEREUS™ development program for GLP-1 receptor agonists prevention named Thetis with results expected in 2026 (2026-05-07 filing)
- BYSANTI™ Phase III adjunctive treatment for MDD with results expected in Q1 2027 (2026-05-07 filing)
- Fanapt® LAI formulation development includes hypertension indication (2026-05-07 filing)
- Removed:
- Commercial portfolio comprised of three products reduced to statement of five products (2025-10-30 filing had three; 2026-05-07 filing has five)
- Tradipitant referred to as VLY-686 and NK-1 receptor antagonist in older filing (removed from newer filing's pipeline description with name change)
- Fanapt® described as treatment for bipolar I and schizophrenia only; hypertension removed from approved indication in older filing (2025-10-30 filing)
- Bysanti™ described as active metabolite of Fanapt® in older filing (2025-10-30 filing)
- Fanapt® LAI formulation listed for schizophrenia only in older filing (2025-10-30 filing)
- Bysanti™ in development section for acute treatment of bipolar I and schizophrenia in older filing (now approved in 2026-05-07 filing)
- Reference to FDA collaborative framework agreement dated October 1, 2025 (2025-10-30 filing only)
- References to HETLIOZ® sNDA for jet lag disorder under review (2025-10-30 filing)
- References to tradipitant clinical hold and motion sickness NDA under FDA review with December 30, 2025 PDUFA date (2025-10-30 filing)
- Reference to Bysanti™ NDA under review with February 21, 2026 PDUFA date (2025-10-30 filing)
- Commercial focus on Fanapt®, HETLIOZ®, and PONVORY® in U.S. and select international markets (2025-10-30 filing)
- Reworded:
- Commercial portfolio described as 'three products' (2025-10-30) changed to 'five products' including BYSANTI™ and NEREUS™ (2026-05-07)
- Fanapt® Q1 2025 comparison metrics: TRx up 32% and NBRx up 76% (2026-05-07) replaces Q3 2024 comparison: TRx up 35% and net sales up 31% (2025-10-30)
- VQW-765 described as 'alpha-7 nicotinic acetylcholine receptor partial agonist' (2026-05-07) versus 'nicotinic acetylcholine receptor partial agonist' (2025-10-30)
- PONVORY® indication order changed from 'psoriasis and ulcerative colitis' (2025-10-30) to 'ulcerative colitis and psoriasis' (2026-05-07)
- NEREUS™ indications expanded from motion sickness in development to FDA-approved prevention of motion-induced vomiting (2026-05-07)
- Bysanti™ development status changed from NDA under review (2025-10-30) to FDA-approved product (2026-05-07)
- Tradipitant (VLY-686) removed as separate pipeline entry; references consolidated as NEREUS™ (2026-05-07)
- Annual Report reference year changed from 2024 (2025-10-30) to 2025 (2026-05-07)
- Notes:
- Text comparison was truncated in older filing MD&A section; final accounting policy paragraph incomplete
- Accession numbers and URLs provided match stated filing dates and company (VNDA)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for VNDA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VNDA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 16,399,766
- Reported value $100,366,570
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about VNDA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
VNDA had 7,831,971 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
VNDA had 13.0% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.45 days to cover at the same settlement.
- Reported short interest (shares) 7,831,971
- Short interest (% of shares outstanding) 13.0%
- Prior settlement (shares) 8,495,290
- Reported change -7.81%
- Days to cover (reported) 6.45
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Otsuka Pharmaceutical
- Lundbeck
- Alkermes (ALKS)
- Johnson & Johnson (JNJ)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Teva Pharmaceutical (TEVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VNDA vs…
VANDA PHARMACEUTICALS INC is found in…
Frequently asked questions
What does VANDA PHARMACEUTICALS INC (VNDA) do?
Vanda Pharmaceuticals is a global biopharmaceutical company focused on the development and commercialization of innovative therapies for high unmet medical needs in psychiatry and neurology. The company utilizes pharmacogenetics and pharmacogenomics to guide its drug discovery, clinical development, and commercial positioning.
What sector is VANDA PHARMACEUTICALS INC (VNDA) in?
VANDA PHARMACEUTICALS INC (VNDA) is classified in the Health Care sector. Its industry is specialty pharmaceuticals. It trades on NASDAQ.
Who are VANDA PHARMACEUTICALS INC's (VNDA) competitors?
Notable peers of VANDA PHARMACEUTICALS INC (VNDA) include Otsuka Pharmaceutical, Lundbeck, Alkermes, Johnson & Johnson and Novartis. This peer set is informational only — not financial advice.
Is VANDA PHARMACEUTICALS INC (VNDA) overbought or oversold right now?
VANDA PHARMACEUTICALS INC (VNDA) is currently in oversold territory (its 14-day RSI is 27, below 30) (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VNDA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.